2026 Election Results

All eligible to vote Principal Investigators (672) from EBMT full membership centres were invited to vote online for the nominated, endorsed and approved Working Party Chair candidates for 2026, in addition to approving the activity reports (President, Secretary and Treasurer) and bylaws amendments. 299 of 672 ballots were cast.

Voting took place online from Tuesday 10 March 2026. The elections results were announced live at the General Assembly Meeting on Tuesday 24 March, during the 52nd Annual Meeting of the EBMT.

You will find the results of this online election below:

EBMT Working Party Chairs

Acute Leukaemia Working Party

I am deeply honoured to have been elected Chairperson of the Acute Leukemia Working Party. 
Our priorities are to enhance scientific productivity and promote the publication of high-quality, methodologically robust studies, while strengthening collaboration with other working parties and international partners to evaluate emerging strategies. We also aim to encourage the active involvement of young members, whose ideas and energy are vital to our future. Finally, we will support the development and application of advanced statistical and analytical methods, essential for integrating the increasingly complex clinical, molecular, and genomic data that are transforming our field.

Chronic Malignancies Working Party

I am very happy and honoured to have been elected Chair of the EBMT Chronic Malignancies Working Party to serve all members around scientific issues related to this working party. One of my challenges would be to improve information regarding molecular alterations by being closer to centres, with optimisation for data collection and collaborations with extra-EBMT groups, so as to improve the quality of the studies.
Our group can count on plenty of motivated people that would work together to produce high-quality work to serve patients and optimise their care.

Cellular Therapy and Immunobiology Working Party 

I have seen how evidence generated by our community shapes innovation and access through my work bridging immune biology, clinical practice, and regulation, including leadership roles within EBMT. This perspective is essential for the CTIWP’s next phase. As cellular immunotherapies enter a period where scientific progress, regulatory requirements, and access are increasingly intertwined, the CTIWP must actively address this intersection. As Chair, I will focus on empowering investigator-led projects, strengthening collaboration across Working Parties, and ensuring that high-quality science translates into equitable patient access. If we do not actively define this space, others will.

JACIE Working Party 

I am honoured by the trust the EBMT and JACIE community has placed as I take on the role of Chair of the JACIE Working Party and I look forward to building on the solid foundations established by Lynn Manson and John Snowden.

JACIE is at its heart about quality and achieving the best outcomes for people receiving cell therapy and stem cell transplants. The field of cell therapy is changing rapidly, and we will work to ensure JACIE adapts to reflect and support these changes and that we will work closely with transplant and cell therapy centres and all stakeholders to ensure that the benefits of the rapidly advancing science are translated effectively to benefit all patients. JACIE as a Working Party now has a greater opportunity for education and scientific publications and we are looking forward to this new chapter in the JACIE story.

EBMT 2025 Annual Activity Reports Approval

In addition to voting online for the nominated candidates, PIs were also asked to approve the President's, Secretary's and the Treasurer's reports and the Bylaw Amendments Approval in advance of the Annual General Assembly Meeting 2026.

EBMT President's Activity Report 2025

EBMT Treasurer's Annual Report for 2025

EBMT Secretary's Annual Report for 2025

EBMT 2026 Bylaw Amendments Approval

2026 Committee Chair Appointments

Following validation and Board approval, the following appointments have been confirmed:

Fabio Ciceri – Registry Committee Chair
Arnon Nagler – Global Committee Chair
Donal McLornan – Practice Harmonisation & Guidelines Chair
Dimitris Protogiros – Equality, Diversity & Inclusion Committee Chair
Andrea Linke & Jacqueline del Castillo – Patient & Advocacy Committee Co-Chairs
Rick Admiraal – Pharmacist Committee Chair

All chairs will assume their roles immediately after the conclusion of the Annual Meeting 2026 in Madrid, ensuring a smooth leadership transition.

Outgoing Board Members

We would like to thank the following outgoing Board Members for their support and commitment to the Scientific Council and Board of Association during their mandates:

Annalisa Ruggeri - EBMT Cellular Therapy & Immunobiology Working Party Chair (2022–2026) and Scientific Council Representative with the Educational Portfolio (2024–2026)
Donal McLornan - EBMT Chronic Malignancies Working Party Chair (2022–2026) and Scientific Council Co-Chair with the Research and Sciences Portfolio (2023–2026)
Fabio Ciceri - EBMT Acute Leukaemia Working Party Chair (2022–2026) and Scientific Council Chair with the Research and Sciences Portfolio (2023–2026)
Michelle Kenyon - EBMT Nurses Group President (2019–2025) and Member of the Board of Association (2019–2026)
Anna Sureda Balari - EBMT President, Member of the Executive Committee, and Board of Association (2022–2026)